Market Access News | pharmaphorum

News

Elderly woman holds her head in her hands; black and white image

Axsome breaks new ground in Alzheimer's with Auvelity OK

Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.

News

NICE backs UCB drug as first uncontrolled gMG therapy

UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.

News

Norgine gets first EU approval for WHIM syndrome therapy

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.

News

GSK eyes October FDA verdict on chronic hep B drug

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.

News

FDA grants three priority vouchers to psychedelics

The FDA dropped a surprise Friday announcement that three more National Priority Vouchers would be given to a trio of psychedelics companies.

News

FDA declines to approve AbbVie's Botox follow-up

AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.

Axsome breaks new ground in Alzheimer's with Auvelity OK

NICE backs UCB drug as first uncontrolled gMG therapy

Norgine gets first EU approval for WHIM syndrome therapy

GSK eyes October FDA verdict on chronic hep B drug

FDA grants three priority vouchers to psychedelics

FDA declines to approve AbbVie's Botox follow-up

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks